Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jin-Hyuk Jeong has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mechanofusion-assisted magnesium stearate surface modification enhances dispersion and aerodynamic performance of carrier-based nintedanib inhalable dry powder formulations

    by Woong-Young Jung, So-Jeong Jeong, Yu-Rim Choi, Seungsu Kim, Jin-Hyuk Jeong, Chang-Soo Han, Ji-Hyun Kang, Dong-Wook Kim, Chun-Woong Park

  • Design of inkjet-printed nicotine buccal films with folding-dependent drug release

    by Jin-Hyuk Jeong, SeongHun Jung, Ji-Hyun Kang, Dong-Wook Kim, Dae Hwan Shin, Chun-Woong Park

  • Open Access

    Design of Inkjet-Printed Nicotine Buccal Films with Folding-Dependent Drug Release

    by Jin-Hyuk Jeong, SeongHun Jung, Ji-Hyun Kang, Dong-Wook Kim, Dae Hwan Shin, Chun-Woong Park

    Nicotine replacement therapy (NRT) remains one of the most widely used strategies for smoking cessation. However, currently available products are limited by fixed-dose strengths and poor adaptability to release behavior. In this study, an inkjet-printed nicotine buccal film platform was developed to enable quantitative dose control and folding-dependent modulation of drug release. Five aqueous nicotine inks were prepared to evaluate printability. Nicotine deposition showed strong correlations with print number, printed area, and calculated Z value, confirming predictable and digitally controllable drug loading. Among the tested substrates, the polyethylene oxide (PEO)-based ML8 formulation showed the sharpest printed boundary and the highest elongation at break and was selected as optimal. In the ML8 system, the casting thickness influenced the mechanical flexibility and early stage drug release without compromising the printing quality or adhesive behavior. Physicochemical analyses using differential scanning calorimetry (DSC), X-ray diffraction (XRD), and Fourier-transform infrared spectroscopy (FT-IR) showed that nicotine remained chemically and thermally stable after printing, whereas the intrinsic semi-crystalline structure of the PEO-rich substrate was preserved. Notably, drug release from the ML8 films could be modulated by the folding configuration alone, without altering the formulation composition. Increasing the number of folds progressively slowed the drug release and reduced the Korsmeyer–Peppas release rate constant, revealing that folding can serve as a practical structural parameter for release control. Overall, this study established inkjet-printed nicotine buccal films as a digitally fabricated platform in which the dose is controlled by printing parameters and the release is tuned by structural design.

  • Open Access

    Morphology-driven zinc oxide biointeractive carriers with biological barrier modulating effects for pulmonary delivery of liraglutide

    by Jin-Hyuk Jeong, Chang-Soo Han, Ji-Hyun Kang, Dong-Wook Kim, Chun-Woong Park

    Pulmonary delivery provides a noninvasive route for systemic administration of biologics, yet efficient lung deposition and permeation across pulmonary bar


  • Open Access

    Co-Spray-Dried Macitentan–Tadalafil with Leucine Microparticles for Inhalable Delivery in Pulmonary Arterial Hypertension

    by Chang-Soo Han, Jin-Hyuk Jeong, Hyeon Woo Moon, Yechan Song, Chun-Woong Park

    Background/Objectives: This study developed a macitentan (MAC)–tadalafil (TAD) dry powder inhalation preparation using suspension-based spray drying to enhance pulmonary delivery and reduce systemic exposure to oral combination therapy in patients with pulmonary arterial hypertension (PAH). Methods: MAC–TAD composite powders were prepared by physically mixing or spray-drying aqueous ethanol suspensions at various MAC:TAD ratios. The lead M2-T8 was co-spray-dried with 5, 25, or 50% (w/w) L-leucine. Results: Spray-dried formulations exhibited narrower and more uniform particle size distributions (Dv50 2–6 µm; Dv90~10 µm) and higher emitted dose values than the physical mixtures. In the M2-T8 spray-dried formulation, TAD exhibited an elevated fine particle dose (FPD) (3073.45 ± 1312.30 μg), demonstrating improved aerosolization relative to the physical mixture, even outperforming the TAD-higher M1-T9 formulation (2896.83 ± 531.38 μg), suggesting that favorable interparticle adhesive interactions were developed during co-drying. The incorporation of 25% L-leucine produced the greatest improvement in dispersibility, increasing the FPD by ~31% for MAC and 17% for TAD, whereas excessive L-leucine (50%) reduced the aerosol performance. Powder X-ray diffraction and differential scanning calorimetry confirmed the retention of the MAC and TAD crystallinities, with L-leucine remaining either amorphous or partially crystalline. Conclusions: Suspension-based spray drying yielded MAC–TAD composite formulations with improved uniformity and aerosol performance. The optimized 2:8 formulation containing 25% L-leucine demonstrated the most efficient pulmonary deposition, supporting its potential as an inhaled combination therapy for the treatment of PAH.

  • Machine learning-based prediction of aerodynamic performance in arformoterol-lactose dry powder inhaler formulations using surface roughness features

    by Jin-Hyuk Jeong, Soyeon Hong, Ji-Hyeon Kwon, Soyoun Yang, Dong-Wook Kim, Nan Song, Hyunsouk Cho, Chun-Woong Park


  • Open Access

    Development and Evaluation of a Modified Fixed-Dose Combination Antihypertensive Tablet Containing S-Amlodipine Besylate: A Bioequivalence and Stability Study

    by Hyeon Woo Moon, Jin-Hyuk Jeong, Chun-Woong Park

    Background/Objectives: Fixed-dose combination (FDC) antihypertensive medications containing olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide are widely used for the treatment of essential hypertension. Although effective, the use of racemic amlodipine, which contains both active S(−)-amlodipine and inactive R(+)-amlodipine, has been associated with dose-dependent adverse effects, such as peripheral edema. S-amlodipine, a pharmacologically active enantiomer, provides comparable antihypertensive efficacy at half the dose with a lower incidence of side effects. Methods: In this study, a modified FDC formulation was developed by replacing racemic amlodipine with S-amlodipine to enhance tolerability while maintaining therapeutic efficacy. Results: A bilayer tablet design was employed to minimize the formation of impurities and ensure formulation stability, which was confirmed under stress and accelerated conditions. In vitro dissolution testing demonstrated pharmaceutical equivalence with the marketed reference FDC, and an in vivo pharmacokinetic study confirmed bioequivalence. Conclusions: These results suggest that the newly developed S-amlodipine besylate-containing FDC tablet is a viable alternative to existing olmesartan/amlodipine/hydrochlorothiazide combinations, offering comparable efficacy and pharmacokinetic properties with the potential for improved safety and patient adherence in the management of hypertension.


  • Open Access

    Impact of Different Hydrate Forms of Magnesium Stearate as a Flow Control Agent on the Physical Stability and Inhalation Efficiency of Carrier-Based Formulations

    by Jin-Hyuk Jeong, Jaewoon Son, Ji-Hyeon Kwon, Chang-Soo Han, Chun-Woong Park

    Objectives: This study aimed to evaluate the impact of the different hydration states of magnesium stearate (Mg.st) anhydrate (AH), monohydrate (MH), and dihydrate (DH) on the aerodynamic performance and stability of carrier-based dry powder inhalation (DPI) formulations using arformoterol and budesonide as model drugs. Methods: DPI formulations were prepared using Inhalac 251 lactose and Mg.st in various hydrated forms. The physicochemical properties of Mg.st were characterized using powder X-ray diffraction, differential scanning calorimetry, Fourier-transform infrared spectroscopy, Karl Fischer titration, dynamic vapor absorption, and Raman imaging. The aerodynamic performance was assessed employing a next-generation impactor under initial and accelerated conditions (40 °C, 75% relative humidity). Results: Mg.st-MH exhibited the highest crystallinity and the most stable moisture sorption profile, and showed the smallest particle size within the formulation as observed in the Raman images. Formulations containing Mg.st-MH demonstrated significantly higher fine particle fractions for both arformoterol (51.02 ± 5.16%) and budesonide (61.98 ± 4.09%) compared to formulations with Mg.st-AH or -DH forms. Mg.st-MH also exhibited improved performance retention under accelerated conditions, correlating with its physicochemical stability. Conclusions: The monohydrate form of magnesium stearate was the most effective force control agent, which reduced interparticulate interactions, thereby enhancing the inhalation efficiency and formulation stability. Thus, selecting an appropriate hydration form of Mg.st can improve DPI performance.


  • Open Access

    Lung-Targeted Itraconazole Delivery Using PVA-Based Nano-in-Microparticles for Improved Treatment of Pulmonary Aspergillosis

    by Jin-Hyuk Jeong, Hee-Sung Lee, Jae-Cheol Choi, Ji-Hyun Kang, Dong-Wook Kim, Chan-Su Park, Chun-Woong Park

    Purpose: Pulmonary aspergillosis (PA) presents a substantial therapeutic challenge, especially in immunocompromised patients, where conventional systemic treatments like oral and intravenous routes often result in limited efficacy and increased adverse effects. This study focuses on the development and evaluation of an inhalable itraconazole (ITZ) formulation within a nanoparticles-in-microparticles (NIM) system. Methods: Polyvinyl alcohol 500 (PVA), used in varying concentrations, played a crucial role as a stabilizer in both the wet bead milling and spray drying processes, enhancing drug release and aerodynamic performance. The influence of PVA ratios on drug penetration into pulmonary mucus and interactions with pulmonary defense mechanisms were thoroughly investigated through in-vitro simulations. Results: Pharmacokinetic analysis in Sprague-Dawley (SD) rats revealed enhanced distribution of ITZ-NIMs in pulmonary tissues and bronchoalveolar lavage fluid (BALF), representing a significant improvement in localized drug concentration. Efficacy against Aspergillus fumigatus was confirmed by a reduction in galactomannan levels, inhibition of fungal growth in lung tissues, and increased survival rates. Importantly, pulmonary delivery of ITZ significantly reduced hepatotoxicity markers, including alanine aminotransferase (ALT) and alkaline phosphatase (ALP), when compared to oral administration. Conclusion: The incorporation of PVA in NIM technology demonstrated not only improved pulmonary targeting and drug release but also minimized systemic toxicity, highlighting the potential of nanoparticle-based inhalation systems in treating respiratory fungal infections like aspergillosis. These findings emphasize the pivotal role of PVA in the formulation, stability, and therapeutic efficacy of NIM-based drug delivery systems for pulmonary applications, advancing the use of nanoparticle technology in respiratory drug delivery.


  • Recent quality by design approaches for process optimization and quality enhancement of dry powder inhalers

    by Jin-Hyuk Jeong, Ji Hoon Choi, Je Hwa Yoo, Yu-Rim Choi, Ji-Hyun Kang, Dong-Wook Kim, Chun-Woong Park